Arany I, Rady P, Tyring S K
Department of Microbiology, University of Texas Medical Branch, Galveston.
Viral Immunol. 1993 Winter;6(4):255-65. doi: 10.1089/vim.1993.6.255.
Even though the "low-risk" human papillomavirus (HPV) diseases, such as condyloma acuminatum, rarely progress to malignancy, their high incidence evidences the need for a better understanding of molecular interactions between these viruses and the epithelium. Our study examined the contribution of altered expression of certain cytokines and antioncogenes to the hyperproliferative properties of HPV-related skin lesions. The "low-risk" human papillomavirus types (HPV 6 or 11) were determined by in situ hybridization and PCR amplification followed by direct sequencing using consensus primers from the highly conserved L1 region in six different condylomas. mRNA levels of certain cytokines (e.g., TGF-beta 1, IFN-beta), tumor suppressor genes (RB, p53), c-myc, epidermal growth factor receptor, and cdc2 kinase were measured by RT/PCR. A characteristic change in mRNA levels of those genes was found in condylomas compared to that of the expression levels of uninfected skin. Western blot experiments demonstrated a higher proportion of the hyperphosphorylated form of RB protein and a higher level of cdc2 kinase and c-myc, but low p53 and TGF-beta 1 levels in condylomas. These data reflect a higher proliferative state of those condylomas compared to the normal skin, suggesting a direct or indirect involvement of "low-risk" HPVs in interaction with the cellular cytokine/antioncogene system providing growth advantage to those infected cells.
尽管“低风险”人乳头瘤病毒(HPV)疾病,如尖锐湿疣,很少发展为恶性肿瘤,但其高发病率表明有必要更好地了解这些病毒与上皮细胞之间的分子相互作用。我们的研究检测了某些细胞因子和抗癌基因表达改变对HPV相关皮肤病变过度增殖特性的影响。通过原位杂交和PCR扩增,随后使用来自六个不同尖锐湿疣高度保守L1区域的共有引物进行直接测序,确定“低风险”人乳头瘤病毒类型(HPV 6或11)。通过RT/PCR测量某些细胞因子(如TGF-β1、IFN-β)、肿瘤抑制基因(RB、p53)、c-myc、表皮生长因子受体和cdc2激酶的mRNA水平。与未感染皮肤的表达水平相比,在尖锐湿疣中发现了这些基因mRNA水平的特征性变化。蛋白质印迹实验表明,尖锐湿疣中RB蛋白的高磷酸化形式比例更高,cdc2激酶和c-myc水平更高,但p53和TGF-β1水平较低。这些数据反映出与正常皮肤相比,这些尖锐湿疣处于更高的增殖状态,表明“低风险”HPV直接或间接参与与细胞细胞因子/抗癌基因系统的相互作用,为那些感染细胞提供生长优势。